Xiang Lin

发表

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

Jin-hai Tang, Zefei Jiang, Xiaoyu Zhu, 2022, BMC Medicine.

Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials

Yiping Zhang, Xiaoyu Zhu, T. Jiang, 2023, Experimental Hematology & Oncology.

Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial.

Yi-long Wu, W. Zhong, Lunxu Liu, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.